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Background. Induced sputum (IS) may provide diagnostic information about the etiology of pneumonia. The safety of this 
procedure across a heterogeneous population with severe pneumonia in low- and middle-income countries has not been described.
Methods. IS specimens were obtained as part a 7-country study of the etiology of severe and very severe pneumonia in hos-
pitalized children <5 years of age. Rigorous clinical monitoring was done before, during, and after the procedure to record oxygen 
requirement, oxygen saturation, respiratory rate, consciousness level, and other evidence of clinical deterioration. Criteria for IS con-
traindications were predefined and serious adverse events (SAEs) were reported to ethics committees and a central safety monitor.
Results. A total of 4653 IS procedures were done among 3802 children. Thirteen SAEs were reported in relation to collection of 
IS, or 0.34% of children with at least 1 IS specimen collected (95% confidence interval, 0.15%–0.53%). A drop in oxygen saturation 
that required supplemental oxygen was the most common SAE. One child died after feeding was reinitiated 2 hours after undergoing 
sputum induction; this death was categorized as “possibly related” to the procedure.
Conclusions. The overall frequency of SAEs was very low, and the nature of most SAEs was manageable, demonstrating a low-
risk safety profile for IS collection even among severely ill children in low-income-country settings. Healthcare providers should 
monitor oxygen saturation and requirements during and after IS collection, and assess patients prior to reinitiating feeding after the 
IS procedure, to ensure patient safety.
Keywords. PERCH; induced sputum; very severe pneumonia; severe pneumonia; safety.
 
Induced sputum (IS) examination in immunocompro-
mised children for Pneumocystis jirovecii and for suspected 
Mycobacterium tuberculosis is the standard of care [1–4]. Given 
its utility in this subset of children, there has been increased 
interest in its use for pneumonia diagnosis in children more 
generally [5]. While several small studies have found that the 
IS procedure was well tolerated in children, and produced qual-
ity specimens for pneumonia pathogen identification [2–4, 6], 
there have been no large-scale studies evaluating the safety of 
this procedure in children with severe and very severe pneumo-
nia. We describe the safety profile of the IS procedure performed 
at 9 sites in 7 countries, among a heterogeneous population of 
children 1–59 months of age hospitalized with severe and very 
severe pneumonia.
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METHODS
IS specimens were collected from cases enrolled in the Pneumonia 
Etiology Research for Child Health (PERCH) study, a 9-site, 
7-country case-control study of World Health Organization 
(WHO)–defined severe or very severe pneumonia in hospital-
ized children and community controls aged 1–59 months, to esti-
mate the causes of pneumonia in children. The study design and 
methods have been described elsewhere, and training materials 
as well as study documents are publically available describing 
the standardized methods that were used across heterogeneous 
settings and populations [7–10]. The PERCH study protocol 
was approved by the institutional review board or ethical review 
committee at each of the study site institutions and at the Johns 
Hopkins Bloomberg School of Public Health. Parents or guardi-
ans of all participants provided written informed consent.
Protocol Development
During the PERCH study design phase, experts in pediatric 
respiratory disease were asked to synthesize the evidence on 
the safety and utility of IS collection in children [5]. After con-
sidering the risks and benefits, 16 pediatric pneumonia experts 
endorsed the collection of IS in PERCH, particularly for detec-
tion of tuberculosis and pneumocystis pneumonia. These same 
experts also recommended that IS be obtained from all PERCH 
cases using nebulization with hypertonic saline, excepting those 
children with a clear contraindication, such as hypoxia [5].
Of the 9 sites (in 7 countries) selected to be part of PERCH 
in 2010, 2 (Kenya and South Africa) were already collecting IS 
specimens as part of routine clinical care from children hospital-
ized with pneumonia, and 1 site solely for study purposes (The 
Gambia). A standardized operating procedure (SOP) based on 
the techniques used by these sites was developed and agreed 
upon by all investigators [11]. To facilitate cross-site collabora-
tion and standardization of methods, teams without experience 
in IS collection were trained by experienced study investigators 
from sites using the procedure routinely. Because 6 of the 9 sites 
initiated sputum collection as a new study procedure, we imple-
mented standardized clinical monitoring for all sites to assess the 
procedure safety and ensure the safety of study participants [12].
IS Procedure
The IS procedure is described in detail in accompanying papers 
[13, 14]. In brief, at the time of IS collection, a nebulized β-ag-
onist was administered to enrolled PERCH cases, followed by 
inhaled nebulized 5% hypertonic saline (to induce expecto-
ration). Sputum was collected using a sterile catheter passed 
through the nose and suction was applied to aspirate the con-
tents of the posterior nasopharynx. Without suction, the cath-
eter was then removed from the nose and flushed with sterile 
normal saline into a closed mucous trap. The specimen was col-
lected within 24 hours of admission whenever possible, among 
children without contraindications (see below).
In South Africa, >1 IS specimen was routinely collected from 
each child to enhance the detection of M. tuberculosis. At other 
sites, an additional IS specimen for tuberculosis diagnosis was 
collected at the discretion of the clinical provider. Multiple 
specimens from the same child were not pooled, as the second 
specimen was collected >24 hours after the first for children in 
whom tuberculosis was suspected.
Contraindications to collection of IS included oxygen saturation 
<92% on supplemental oxygen, inability to protect airway, severe 
bronchospasm, seizure within the preceding 24 hours, or deemed 
inadvisable by the treating physician. Children who underwent 
IS collection were closely monitored before, during, and after the 
procedure. Clinical measures including oxygen saturation and oxy-
gen requirement, respiratory rate, and consciousness level (using 
the alert, voice, pain, unresponsive [AVPU] scale) were recorded 
immediately before and after the IS procedure, as well as at 30 
minutes, 2 hours, and 4 hours following the procedure. Criteria for 
stopping the procedure were oxygen saturation ≤88% for >60 sec-
onds or oxygen saturation of 89%–91% for >60 seconds despite an 
increase in supplemental oxygen. If after a period of stabilization 
or rest the child’s respiratory status improved to their preprocedure 
baseline status, IS collection was resumed when oxygen satura-
tion was ≥92% for 5 minutes or more. If the oxygen requirement 
remained greater than the requirement prior to the procedure, 
the IS procedure was only restarted after careful evaluation of the 
child’s clinical status and stability, noting possible disease progres-
sion and the magnitude of change in oxygen requirement.
Severe Adverse Event Reporting
In collaboration with the ethical review boards that approved 
the study, 4 criteria were established for categorizing a change in 
clinical status as a serious adverse event (SAE) in PERCH cases 
undergoing IS specimen collection. These 4 conditions were 
reported as SAEs if they occurred any time between the initiat-
ing the procedure and 4 hours postprocedure: (1) death (for any 
reason); (2) drop in oxygen saturation by ≥5% for at least 15 min-
utes; (3) new onset of unconsciousness or prostration; and (4) 
new requirement for bronchodilator or increased frequency of 
bronchodilator treatment. Each site assigned an independent cli-
nician to be the site safety monitor for the study, and when an SAE 
occurred, the study staff completed a report describing the event. 
The site safety monitor was responsible for reviewing each SAE 
report and determining whether the event could be attributed to 
a specific procedure. Relatedness was assigned as definitely, prob-
ably, possibly, and probably not. Reports were then submitted for 
review to the PERCH study-wide safety monitor, a physician 
who had no other investigator role in the PERCH study, and were 
forwarded to the Johns Hopkins University Institutional Review 
Board (IRB) and the site ethical review board(s).
The above monitoring and SAE reporting criteria were devel-
oped to safeguard children with severe respiratory illness from 
developing complications due to a study procedure. At least 1 
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study investigator from each site (usually the primary study cli-
nician) participated in a PERCH Clinical and Epidemiology 
Working Group that reviewed the contraindications for IS collec-
tion, the criteria for defining SAEs, and the SAEs as they occurred.
Statistical Analysis
We performed a descriptive analysis, calculating frequencies 
for categorical variables and medians and interquartile ranges 
for continuous variables, to compare the safety parameters at 
the various clinical monitoring time points. Given that the 
PERCH guidelines specified collection of 1 IS specimen and 
that children from whom a second IS specimen was collected 
may have differed from those with 1 IS, risks were calculated 
separately for the first IS and the second IS. Also, separately 
for the first and second IS, McNemar χ2 test was used to assess 
differences in oxygen requirement, saturation, and respiratory 
rate before and after the IS procedure.
RESULTS
Over the course of a 24-month enrollment period at each 
site, 3802 of 4232 (90%) enrolled PERCH patients underwent 
Table 1. Characteristics of Pneumonia Etiology Research for Child Health (PERCH) Study Cases With Induced Sputum Collection
Characteristic
Children With
1 IS Specimen
(n = 2951)
Children With
>1 IS Specimen
(n = 851)a
All Children
With IS Specimen
(n = 3802)
All IS Specimens
(N = 4653)
Age
 1 mo to <6 mo 1139 (38.6) 410 (48.2) 1549 (40.7) 1959 (42.1)
 6–11 mo 649 (22.0) 212 (24.9) 861 (22.6) 1073 (23.1)
 12–23 mo 705 (23.9) 156 (18.3) 861 (22.6) 1017 (21.9)
 24–59 mo 458 (15.5) 73 (8.6) 531 (14.0) 604 (13.0)
Severity
 Severe 2114 (71.6) 599 (70.4) 2713 (71.4) 3312 (71.2)
 Very severe 837 (28.4) 252 (29.6) 1089 (28.6) 1341 (28.8)
Sex
 Female 1210 (41.0) 385 (45.2) 1595 (42.0) 1980 (42.6)
 Male 1741 (59.0) 466 (54.8) 2207 (58.0) 2673 (57.4)
HIV statusb
 Positive 112 (3.8) 93 (10.9) 205 (5.4) 298 (6.4)
 Negative 2527 (85.6) 751 (88.2) 3278 (86.2) 4029 (86.6)
 Unknown 312 (10.6) 7 (0.8) 319 (8.4) 326 (7.0)
HIV exposurec
 Exposed 267 (9.0) 353 (41.5) 620 (16.3) 973 (20.9)
 Unexposed 2370 (80.3) 460 (54.1) 2830 (74.4) 3290 (70.7)
 Unknown 314 (10.6) 38 (4.5) 352 (9.3) 390 (8.4)
Receiving supplemental oxygen
 At admission 500 (16.9) 702 (82.5)a 1202 (31.6) 1904 (40.9)
 Everd 808 (27.4) 767 (90.1) 1576 (41.4) 2343 (50.4)
 Immediately prior to IS 524 (17.8) 577 (67.8)e 1101 (29.0) 1580 (34.0)
Country/study site
 Kilifi, Kenya 550 (18.6) 44 (5.2) 594 (15.6) 638 (13.7)
 Basse, The Gambia 588 (19.9) 8 (0.9) 596 (15.7) 604 (13.0)
 Bamako, Mali 544 (18.4) 0 (0.0) 544 (14.3) 544 (11.7)
 Lusaka, Zambia 517 (17.5) 1 (0.1) 518 (13.6) 519 (11.2)
 Soweto, South Africa 56 (1.9) 785 (92.2) 841 (22.1) 1626 (34.9)
 Nakhon Phanom and Sa Kaeo, Thailand 190 (6.4) 1 (0.1) 191 (5.0) 192 (4.1)
 Dhaka and Matlab, Bangladesh 506 (17.2) 12 (1.4) 518 (13.6) 530 (11.4)
Data are presented as No. (%).
Abbreviations: HIV, human immunodeficiency virus; IS, induced sputum.
aAmong children with >1 IS, 92% were from the South African site where it was standard of care to place children with pneumonia on oxygen.
bHIV negative: negative polymerase chain reaction or enzyme-linked immunosorbent assay (ELISA) results, negative maternal test results at enrollment, or absence of evidence to indicate 
the child is positive in settings with limited HIV transmission (Bangladesh); HIV positive: detectable viral load or HIV seropositive if >12 months old; HIV-unknown: insufficient evidence to 
define HIV status.
cHIV exposed: HIV positive, positive ELISA results (if < 12  months) or positive maternal history (maternal history must be confirmed by maternal serology for seronegative infants 
<7 months); HIV unexposed: (1) documented negative maternal HIV status, (2) <7 months of age with a negative ELISA, or (3) ≥7 months with a negative ELISA result and reported, but 
undocumented, negative maternal history; unknown HIV exposure: insufficient evidence to define HIV exposure status.
dAt admission or 24 hours after IS collection or 48 hours after IS collection.
eChildren with >1 IS included in numerator if they received oxygen immediately before either IS procedure.
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a procedure for induction of sputum. Of these, 851 patients 
had a second procedure, though 92% of these second proce-
dures took place in one site, South Africa. In total there were 
4653 procedures. A  total of 3362 patients (88%) underwent 
an induction of sputum procedure within 24 hours of hospi-
tal admission. For the remaining 439 with the first specimen 
taken after 24 hours, 337 (77%) had an initial contraindica-
tion for the procedure: 102 (23%) had specimen collection 
deemed inadvisable by treating clinicians; 71 (16%) had a sei-
zure in the 24 hours before being assessed for the procedure; 
64 (15%) had severe bronchospasm; 63 (14%) had oxygen sat-
uration <92%; and 37 (8%) were unable to protect their air-
way. The remaining 102 (23%) participants had no specified 
contraindication.
Thirteen SAEs were reported following the IS procedure, rep-
resenting a risk of 0.34% per child undergoing the procedure 
(0.34% for the first IS and 0.0% for the second IS; Table 2). The 
most common SAE (n = 9 [69%]) was a drop in oxygen saturation 
that required an increase in the amount of oxygen administered 
or the initiation of oxygen administration. The clinical condition 
of 8 of these children stabilized within the 4-hour monitoring 
period and 1 child stabilized after a longer period (>12 hours). 
One child met the SAE criteria for increased need for broncho-
dilator nebulization. One child experienced a change in level of 
consciousness, which was attributed by the safety monitors to a 
preexisting condition and not to the procedure itself.
The 13 SAEs included 2 deaths within 4 hours after the pro-
cedure. One of these deaths, in a child 5 months of age with very 
severe pneumonia who developed severe respiratory distress 
2 hours after the IS procedure while breastfeeding and could 
not be resuscitated, was categorized as “possibly related” to IS 
collection. Another death was determined to be “probably not 
related” and occurred in a 16-month-old child with very severe 
pneumonia who was stable for >2 hours after the IS procedure 
but suffered a cardiorespiratory arrest during feeding and could 
not be resuscitated (Table 3). All but 1 of the SAEs occurred at 
some point during the procedure or within 2 hours. Five SAEs 
occurred during the procedure, 1 occurred 30 minutes after the 
procedure, and 6 more occurred between 30 minutes and 2 hours 
post-IS. The single SAE that occurred >2 hours after the pro-
cedure is described above as the 16-month-old child who died 
during feeding approximately 3.5 hours after IS collection, with 
the death being assessed as a likely aspiration event (Table 3).
Children with SAEs were more likely than those without 
SAEs to be human immunodeficiency virus (HIV) exposed 
(46% of children with SAEs vs 18% of children without an 
SAE, P  =  .018) and to have very severe pneumonia (50% vs 
29%, P = .062) (Table 4).
In total, 31 (0.8%) children had the first IS procedure stopped 
because of a drop in oxygen saturation below 88% for >60 sec-
onds. An SAE was reported in 4 of these children (see above) 
and the study clinician was able to restart the IS procedure for 
the remaining 27 children after a period of stabilization (ie, the 
child’s respiratory status improved and oxygen saturation was 
at least 92% for ≥5 minutes). Of the 851 children undergoing 
a second IS procedure, 14 (1.6%) had the procedure stopped 
due to a drop in oxygen saturation below 88% for >60 seconds, 
and the procedure was reinitiated in all 14. There was no change 
in median oxygen requirement before and after the procedure. 
Five children (0.5%) required an oxygen increase of >1  L/
minute immediately after the procedure, compared to their 
baseline status (Table 5). The percentage of children requiring 
supplemental oxygen before the first induced sputum proce-
dure (n = 1091 [29.2%]) dropped to 27.3% (n = 1019) by the 
last clinical monitoring time point at 4 hours postprocedure. 
There were no differences in consciousness level in the imme-
diate period after the procedure. However, 20 children experi-
enced a decrease in their consciousness level when comparing 
immediately before IS and any point during the 4-hour moni-
toring period after IS. Oxygen saturation remained steady at all 
monitoring time points (Table 5). Clinical measures were also 
analyzed separately for children who had a second IS, with no 
clinically significant changes found in that subset of children 
(Supplementary Table 1).
DISCUSSION
The IS procedure was generally well tolerated among a large 
and geographically heterogeneous group of children aged 
1–59 months, hospitalized with WHO-defined severe or very 
severe pneumonia. Serious adverse events were very infrequent 
(n= 13 [0.34%]) as were the subset of SAEs that were assessed 
as probably, possibly, or definitely related to the IS procedure 
Table 2. Serious Adverse Events Reported After Initiating First Induced 
Sputum Procedurea in Pneumonia Etiology Research for Child Health 
(PERCH) Study Cases
Serious Adverse Event No.
Risk of Event per 
Procedure
(n = 3802), %
Total 13 0.34
Drop in oxygen saturation 9 0.23
New requirement or increased need for 
bronchodilator
1 0.03
New onset of unconsciousness or prostration 1 0.03
Death within 4 h of initiating the IS procedure (for 
any reason)
2 0.05
Category of relatedness to IS procedure
 Definitely 4 0.10
 Probably 1 0.03
 Possibly 5 0.13
 Probably not 3 0.08
Abbreviation: IS, induced sputum.
aNo serious adverse events occurred after the second IS. Table restricted to first induced 
sputum procedures to avoid double counting subset of children who underwent a second 
IS procedure in denominator.
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Table 3. Description of Serious Adverse Events Occurring Within 4 Hours of Initiating the Induced Sputum Procedure
Pneumonia 
Severity Age Sex Adverse Event Relatedness Details Outcome
Very  
severe
6 mo F Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Definitely Approximately 10 min into the procedure, the child’s oxygen saturation dropped 
below 92% for >10 min. The child’s clinical status stabilized to stable within an 
hour, and the oxygen saturation stabilized at 95%–98% on room air.
Resolved
Very  
severe
2 mo M New requirement for 
bronchodilator
Definitely During the procedure, child required increased bronchodilator nebulization to stabi-
lize his oxygen saturation levels, which had been steady on supplemental oxygen 
prior to the procedure. Bronchodilators were administered for 15 min, and by 1 h 
postprocedure the child was stable, without continuing need for bronchodilators.
Resolved
Very  
severe
23 mo M Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Definitely Child with cyanotic heart disease experienced a drop in measured oxygen 
saturation from 96% on room air to 74% while receiving nebulized hypertonic 
saline. Oxygen was administered, and the child was clinically stable at 4 h 
postprocedure. Study clinicians and the local safety monitor determined that 
the preprocedure oxygen saturation levels may have been noted incorrectly 
before initiating the IS procedure.
Diagnosis of 
cyanotic 
heart 
disease
Severe 3 mo F Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Definitely Child experienced an increased oxygen requirement between 30 min and 2 h 
postprocedure, and a ward pediatrician recommended a switch from nasal 
prong O2 at 2 L/min to a polymask at 10 L/min based on the advice of the 
attending physician. By 8 h postprocedure, the child had been weaned back to 
nasal prong oxygen and was clinically stable.
Resolved
Very  
severe
3 mo M Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Possibly A child on supplemental oxygen who had stable clinical signs for 2 hours post-
procedure was taken off the ward by a guardian. When study staff located the 
child for the 4-h postprocedure clinical monitoring, he was found to have an 
oxygen saturation of 80%. Supplemental oxygen was delivered; however, the 
child’s guardian continued to remove the oxygen, and the child did not stabilize 
until 48 h after the procedure, as oxygen delivery was continuously disrupted.
Resolved
Severe 1 mo F Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Possibly 30 min after the IS procedure, the child’s oxygen saturation fell to 90% for >10 min. 
Supplemental oxygen was administered; the child’s clinical status resolved by 4 h 
post-IS with an oxygen saturation of 94%–96% on room air.
Resolved
Severe 8 mo M Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Possibly Child’s oxygen saturation fell to 95% from 100% and work of breathing increased 
at 30 min post-IS. An attending physician felt the child required intubation at 
1–2 h post-IS for increased work of breathing. At 4 h post-IS, the child had 
a respiratory rate of 62/min and an oxygen saturation of 98%. The child was 
extubated 7 d later.
Resolved
Severe 3 mo M Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Possibly Oxygen saturation dropped to 67% from 95% on 2 L/min nasal prong oxygen in a 
child with extensive multilobar pneumonia during the NP aspiration part of the 
IS procedure. The procedure was stopped and the oxygen saturation normal-
ized with continued nasal prong oxygen at 2 L/min. At 4 h post-IS, the child had 
a respiratory rate of 86/min and 100% oxygen saturation on 12 L/min polymask 
oxygen. Over the ensuing several hours the child’s respiratory status deteri-
orated, with increasing work of breathing and oxygen requirement leading to 
intubation 12 h following the procedure. The child self-extubated 6 d later.
Resolved
Severe 5 mo F Death Possibly IS collected without event in a child with 98% oxygen saturation on room air. 
Postprocedure respiratory rate was 78 breaths/min. During breastfeeding 
1 h post-IS, the child developed severe respiratory distress and died despite 
resuscitation efforts 2 h after the procedure. The cause of death was assessed 
as a likely aspiration event.
Death
Severe 30 mo M Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Probably During the nebulization with hypertonic saline, the child’s oxygen saturation fell to 
88%–92%. Low flow oxygen was started and administered for 50 min post-
procedure, without attempting to wean the child off oxygen. The child’s oxygen 
saturation was >92% at 2 and 4 h postprocedure on room air.
Resolved
Very  
severe
3 mo M Drop in oxygen satura-
tion <92% requiring 
increased oxygen
Probably 
not
Child experienced a seizure 1 h after the IS procedure. The child had a seizure in 
the 24 h prior to IS collection, which is a contraindication for the procedure. 
However, this was not communicated to the PERCH physician who performed 
the IS procedure. The procedure was stopped during the NP suctioning because 
of transient desaturation to 80% with O2 saturation returning to 95% within 
60 sec of catheter withdrawal. An hour after the IS procedure was started, the 
child experienced another seizure. At 4 h after the IS procedure, the child was 
alert with an oxygen saturation of 99% on 2 L/min nasal prong oxygen.
Resolved
Very  
severe
16 mo F Death Probably 
not
Child with very severe pneumonia and early signs of malnutrition was stable 
more than 2 h after specimen collection. Child developed dyspnea while being 
fed milk by her father and could not be resuscitated. The cause of death was 
assessed as a likely aspiration event.
Death
Very  
severe
11 mo F New onset of 
unconsciousness or 
prostration
Probably 
not/ 
unlikely
Child was stable for 1 h after the IS procedure. 90 min after the procedure, the 
child developed respiratory distress immediately following feeding. Two con-
traindications (history of seizure and inability to protect airways) should have 
been noted for this case. By 4 h post-IS, the child had oxygen saturation of 
85% on room air, which improved to 96% on supplemental oxygen.
Resolved
Abbreviations: IS, induced sputum; NP, nasopharyngeal; O2, oxygen; PERCH, Pneumonia Etiology Research for Child Health.
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(n = 10 [0.26%]). To our knowledge, this is the first large-scale 
study that demonstrates a low rate of SAEs with IS collection 
in hospitalized children with severe or very severe pneumonia 
across multiple settings. This study demonstrates that IS col-
lection can be safely performed in a large sample of children in 
typical resource-constrained hospital; however, vigilant moni-
toring for up to 2 hours postprocedure is necessary.
Our findings are consistent with the low rate of SAEs associ-
ated with IS collection shown in other studies among severely 
ill children [15–18]. In 2 small case series of children with com-
munity-acquired pneumonia in Finland [3] and in 2 PERCH 
pilot studies [6, 19], the IS procedure was found to be well tol-
erated and to produce sputum largely of good quality (defined 
as <10 epithelial cells per high-power field) that contained high 
frequencies of bacterial and viral pathogens.
Two post-IS deaths reported as SAEs were both tempo-
rally associated with reinitiation of feeding following the IS 
procedure. The death that occurred in an infant who reiniti-
ated breastfeeding approximately 2 hours after IS collection was 
assessed as “possibly related” to IS collection; 2 site clinicians, 
the site safety monitor, and 3 clinicians from the PERCH core 
team, including the central safety monitor, could not exclude 
that IS collection may have contributed to respiratory distress. 
The death that occurred in a toddler during cup feeding approx-
imately 2 hours after IS was assessed as “probably not” related 
to IS collection. Following IS collection, it is advisable for a cli-
nician to reassess patients prior to reinitiating feeding to ensure 
that the child’s respiratory status is stable enough to tolerate oral 
intake.
The relatedness of the reported events to the IS procedure is 
difficult to conclude with confidence. All children undergoing 
the IS procedure were hospitalized with severe or very severe 
pneumonia, and many were severely ill. Distinguishing proce-
dure-related clinical deterioration from the natural history of a 
child’s illness is often not possible. It is conceivable that exposing 
children with pneumonia to hypertonic saline nebulized solu-
tion, while provoking coughing as the intended consequence, 
may also in rare circumstances exacerbate the underlying 
illness. With the amount of coughing that is induced, respira-
tory fatigue, aspiration of upper airway secretions, or inade-
quate respiration could impair the child’s clinical status. Among 
the 10 events that were assessed as possibly, probably, or defi-
nitely related, 2 of the children required mechanical ventilation 
after IS and had prolonged hospital stays.
The clinical respiratory stability of children undergoing the 
procedure, as measured by oxygen saturation, oxygen require-
ment, respiratory rate, and consciousness level, remained 
remarkably unaffected by the procedure. Data from some 
children who experienced an SAE within the 4 hours follow-
ing completion of the IS procedure are missing after the time 
of the event and not reflected in Table 5. Although this could 
bias results toward showing no change from baseline, this is 
unlikely to impact the interpretation of results given the small 
number of cases for whom data was not available because of 
an SAE. The oxygen requirement showed a general decreasing 
trend after the procedure and it is possible that IS may benefit 
a child with a congested chest as it loosens secretions and may 
improve airflow. Our findings suggest that frequent monitor-
ing is useful up to 2 hours following the IS procedure, and that 
the PERCH approach was appropriate for the study and may 
be of use for implementation as part of clinical care in hospi-
tal environments. Because only 1 SAE was detected during the 
2- to 4-hour post-IS monitoring period (among 3802 who had 
at least 1 IS), hospital resources may best be directed toward 
frequent oxygen saturation monitoring up to 2 hours post-
procedure. Clinical monitoring data also suggested minimal 
differences at the 2- and 4-hour marks for oxygen saturation, 
a metric that may be readily assessable in resource-limited 
settings.
Table 4. Characteristics of Cases With and Without a Serious Adverse 
Eventa
Characteristics
Cases without 
an SAE 
(n = 3785b)
Cases with 
an SAE 
(n = 13) P Valuec
Site
 Kenya 591 15.6 3 23.1 .99
 The Gambia 592 15.6 2 15.4
 Mali 544 14.4 0 0.0
 Zambia 516 13.6 2 15.4
 South Africa 836 22.1 5 38.5
 Thailand 189 5.0 1 7.7
 Bangladesh 517 13.7 0 0.0
Age
 1–5 mo 1539 40.7 7 53.8 .79
 6–11 mo 858 22.7 3 23.1
 12–23 mo 859 22.7 2 15.4
 24–59 mo 529 14.0 1 7.7
Female 1587 41.9 7 53.8 .41
Severe malnutritiond 504 13.4 3 23.1 .36
Bronchiolitise 740 19.8 3 23.1 .92
HIV positivef 203 5.4 2 15.4 .24
HIV exposedg 614 17.9 6 46.2 .06
Very severe pneumonia 1081 28.6 7 50.0 .06
Abnormal CXRh 1741 53.0 9 75.0 .20
Data are presented as No. (%).
Abbreviations: CXR, chest radiograph; ELISA, enzyme-linked immunosorbent assay; HIV, 
human immunodeficiency virus; PCR, polymerase chain reaction; SAE, serious adverse 
event; SD, standard deviation; WHO, World Health Organization.
aAmong children who underwent an induced sputum procedure.
bThis table does not include data for 4 children who had an SAE related to lung aspirates.
cCalculated from logistic regression (outcome  =  SAE) adjusted for site and age (site is 
adjusted for age only and age is adjusted for site only).
dWHO weight-for-age z score < –3 SDs.
eBronchiolitis reported as admission or discharge diagnoses or concurrent condition.
fHIV positive: detectable viral load or HIV seropositive if >12 months old.
gHIV exposed: HIV positive, positive ELISA results (if < 12 months), or positive maternal 
history (maternal history must be confirmed by maternal serology for seronegative infants 
<7 months).
hAbnormal chest radiograph defined as presence of consolidation and/or other infiltrate.
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The rigorous clinical monitoring done for children in 
PERCH throughout the course of the IS specimen collection 
provides an opportunity to see the overall clinical effects in a 
large and heterogeneous study population of hospitalized chil-
dren. These findings support IS as a relatively safe procedure 
in children with severe pneumonia. Although not statistically 
significant, the risk of an SAE after IS collection was higher 
among HIV-exposed compared with HIV-unexposed children, 
suggesting that a different risk-benefit assessment may apply 
to this subset of children. Clinicians caring for children with 
severe pneumonia have to consider the safety, feasibility, and 
utility of IS, among other factors, when considering whether 
the risk of the procedure is warranted. Our analysis addresses 
only 1 component of this decision matrix; the utility of IS in 
diagnosing the etiology of pneumonia in children is reported 
in a companion article [20]. Additional limitations in the study 
include potential for practice variation and incomplete moni-
toring data (Table 2). Despite standardized protocols and twice-
yearly refresher training on all study SOPs, local differences 
in practice, resources, staffing, and comfort levels with the IS 
procedure may have resulted in procedural, monitoring, and 
reporting variations.
The collection of an IS specimen was well tolerated in hos-
pitalized children aged 1–59 months with severe or very severe 
pneumonia who were eligible for the procedure. Due to the 
potential for clinical deterioration, we recommend that clini-
cians who perform sputum induction in severely ill children 
consider implementing a clinical monitoring protocol to identify 
and treat any complications that may arise, with close attention 
to oxygen saturation levels during and for 2 hours following the 
procedure and a clinical assessment before reinitiating feeding.
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